A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata (BRAVE-AA1)
Diseases of the Integumentary System | Men's Health | Women's Health
What is the purpose of this trial?
This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata.
- Ages18 years - 70 years
- Trial withEli Lilly and Company
- Start Date01/02/2019
- End Date12/30/2018
- Last Updated02/06/2019
- Study HIC#2000023903